Surface Oncology, Inc.
SURF · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | -0.03 | -0.00 |
| FCF Yield | -131.33% | -29.54% | 8.50% | -117.78% |
| EV / EBITDA | -0.82 | -2.80 | 3.68 | -0.53 |
| Quality | ||||
| ROIC | -42.52% | -43.68% | 29.75% | -48.10% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.94 | 0.79 | 0.51 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -38.05% | -44.07% | 28.53% | 6.19% |
| Free Cash Flow Growth | 3.87% | -308.53% | 148.57% | -304.68% |
| Safety | ||||
| Net Debt / EBITDA | -0.08 | -0.02 | -2.04 | 0.38 |
| Interest Coverage | -36.03 | -30.75 | 27.38 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |